Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-01 6:22 pm Purchase | 2024-01-22 | 13G | Dianthus Therapeutics, Inc. DNTH | RA CAPITAL MANAGEMENT L.P. | 2,995,023 9.990% | 2,995,023 (New Position) | Filing History |
| 2024-01-29 4:30 pm Purchase | 2024-01-19 | 13G | Edgewise Therapeutics, Inc. EWTX | RA CAPITAL MANAGEMENT L.P. | 8,909,091 9.600% | 8,909,091 (New Position) | Filing History |
| 2024-01-19 4:30 pm Purchase | 2024-01-18 | 13G | Vaxart, Inc. VXRT | RA CAPITAL MANAGEMENT L.P. | 15,384,615 9.100% | 15,384,615 (New Position) | Filing History |
| 2024-01-12 5:00 pm Purchase | 2024-01-02 | 13G | Longboard Pharmaceuticals, Inc. LBPH | RA CAPITAL MANAGEMENT L.P. | 3,073,119 8.700% | 3,073,119 (New Position) | Filing History |
| 2024-01-11 5:24 pm Purchase | 2024-01-11 | 13D | Solid Biosciences Inc. SLDB | RA CAPITAL MANAGEMENT L.P. | 4,348,828 11.700% | 917,210 (+26.73%) | Filing History |
| 2023-12-29 4:30 pm Purchase | 2023-12-19 | 13G | UroGen Pharma Ltd. URGN | RA CAPITAL MANAGEMENT L.P. | 3,083,550 9.990% | 3,083,550 (New Position) | Filing History |
| 2023-12-26 4:30 pm Purchase | 2023-12-14 | 13G | C4 Therapeutics, Inc. CCCC | RA CAPITAL MANAGEMENT L.P. | 4,878,000 9.900% | 4,878,000 (New Position) | Filing History |
| 2023-12-20 4:30 pm Sale | 2023-12-18 | 13D | Connect Biopharma Holdings Limited CNTB | RA CAPITAL MANAGEMENT L.P. | 3,062,871 5.600% | -2,061,438 (-40.23%) | Filing History |
| 2023-12-14 4:30 pm Sale | 2023-12-12 | 13D | Connect Biopharma Holdings Limited CNTB | RA CAPITAL MANAGEMENT L.P. | 5,124,309 9.300% | -830,702 (-13.95%) | Filing History |
| 2023-12-13 4:30 pm Purchase | 2023-12-11 | 13D | 89bio, Inc. ETNB | RA CAPITAL MANAGEMENT L.P. | 12,875,855 13.600% | 1,041 (+0.01%) | Filing History |
| 2023-12-04 5:20 pm Sale | 2023-11-30 | 13D | Connect Biopharma Holdings Limited CNTB | RA CAPITAL MANAGEMENT L.P. | 5,955,011 10.800% | -1,035,992 (-14.82%) | Filing History |
| 2023-11-27 4:30 pm Purchase | 2023-11-16 | 13G | Third Harmonic Bio, Inc. THRD | RA CAPITAL MANAGEMENT L.P. | 2,033,056 5.000% | 1,498,369 (+280.23%) | Filing History |
| 2023-11-17 4:30 pm Purchase | 2023-11-15 | 13D | Climb Bio, Inc. CLYM | RA CAPITAL MANAGEMENT L.P. | 13,176,403 47.700% | 13,332 (+0.10%) | Filing History |
| 2023-11-14 5:00 pm Sale | 2023-11-14 | 13G | Design Therapeutics, Inc. DSGN | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -2,971,231 (Position Closed) | Filing History |
| 2023-11-06 4:31 pm Purchase | 2023-10-26 | 13G | Harpoon Therapeutics, Inc. HARP | RA CAPITAL MANAGEMENT L.P. | 1,701,570 9.990% | 1,701,570 (New Position) | Filing History |
| 2023-10-30 4:45 pm Purchase | 2023-10-20 | 13G | MacroGenics, Inc. MGNX | RA CAPITAL MANAGEMENT L.P. | 3,764,871 6.100% | 3,764,871 (New Position) | Filing History |
| 2023-10-05 5:09 pm Purchase | 2023-09-26 | 13G | Soleno Therapeutics, Inc. SLNO | RA CAPITAL MANAGEMENT L.P. | 1,233,300 4.600% | 1,233,300 (New Position) | Filing History |
| 2023-09-29 4:54 pm Purchase | 2023-09-19 | 13G | Chimerix, Inc. CMRX | RA CAPITAL MANAGEMENT L.P. | 6,501,624 7.300% | 6,501,624 (New Position) | Filing History |
| 2023-09-25 4:30 pm Purchase | 2023-09-21 | 13D | ARS Pharmaceuticals, Inc. SPRY | RA CAPITAL MANAGEMENT L.P. | 9,459,678 9.900% | 2,700,000 (+39.94%) | Filing History |
| 2023-09-22 4:30 pm Purchase | 2023-09-12 | 13G | CymaBay Therapeutics, Inc. CBAY | RA CAPITAL MANAGEMENT L.P. | 6,940,000 6.200% | 6,940,000 (New Position) | Filing History |